gms | German Medical Science

56. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie e. V. (DGNC)
3èmes journées françaises de Neurochirurgie (SFNC)

Deutsche Gesellschaft für Neurochirurgie e. V.
Société Française de Neurochirurgie

07. bis 11.05.2005, Strasbourg

Intratumoral convection-enhanced Paclitaxel administration in recurrent gliomas : preliminary results

Intratumorale Administration von Paclitaxel in Rezidivgliomen: erste Ergebnisse

Meeting Abstract

Search Medline for

  • corresponding author S. Thomas - Klinik für Neurochirurgie, Klinikum Saarbrücken
  • F.-W. Weber - Klinik für Neurochirurgie, Klinikum Saarbrücken

Deutsche Gesellschaft für Neurochirurgie. Société Française de Neurochirurgie. 56. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie e.V. (DGNC), 3èmes journées françaises de Neurochirurgie (SFNC). Strasbourg, 07.-11.05.2005. Düsseldorf, Köln: German Medical Science; 2005. DocP175

The electronic version of this article is the complete one and can be found online at:

Published: May 4, 2005

© 2005 Thomas et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.




Recurrent gliomas are an almost universal fatal disease within weeks or months following diagnosís of recurrence. The aim of the present study was to investigate the effect of paclitaxel (Taxol) by way ofintratumoral administered using convection-enhanced delivery in recurrent glioblastomas.


In 5 patients with recuurent gliomas (glioblastoma or astrocytoma °3) one or two catheters were placed with the aid of Brainlab neuronavigation. Gadolinium was infused over a time period of 24 hours to evaluate the fluid distribution pattern. MR images were made 4, 8 and 24 hours following the starti of the infusion. Following this placlitaxel infusion was administered with a maximum dose of 18mg over a five-day treatment cycle. MR images were made 24 hours later and consecutively every two months following infusion.


Paclitaxel infusion was tolerated well by all patients with no major side effects. In one patient a meningitis occurred, which was successfully treated with antibiotics. Almost immediately following infusion, MR images revealed a significant reduction of the tumor in the areas predetermined by gadolinium infusion.


Paclitaxel infusion is a safe new method in patients with recurrent gliomas. Long-term outcome has to be determined.